arrow
M

Marcello Arca

Sapienza University of Rome
H指数:60
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term Efficacy and Safety of Lomitapide in Patients with Familial Chylomicronemia Syndrome: Data from an Expanded Access Program

家族性乳糜微粒血症患者中洛米他肽的长期疗效与安全性:扩展性准入项目数据

2025-11-030
OAAI
Patient Experience With Familial Chylomicronemia Syndrome Before and After Olezarsen Treatment: Qualitative Interviews With Clinical Trial Participants

家族性乳糜微粒血症综合征患者在奥莱萨森治疗前后对疾病体验的质性访谈:基于临床试验参与者的研究报告

2025-06-180
OAAI
Lipid-Lowering Therapy and Cardiovascular Prevention in Elderly

降脂治疗与老年人心血管预防

DRUGS
IF14.4
2025-05-080
OA
Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: Over 10 years of efficacy and safety data

阿尔卡, M.; 德埃拉斯莫, L.; 库切尔, M.; 布洛姆, D.J.; 切格拉, J.; 杜尔, P.B.; 桑托斯, R.D.; 奥布莱恩, S. 对纯合子家族性高胆固醇血症患者长期洛美他派治疗的观察:超过10年的疗效和安全性数据. 临床脂质学杂志. 2025, 已接受. [谷歌学术] [交叉引用]

2025-03-290
OAAI
IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)

IDeate-Lung03:一项关于伊凡他单抗德鲁替康(I-DXd)联合阿替利珠单抗(atezo)以及(根据情况)联合卡铂(carbo)作为广泛期(ES)小细胞肺癌(SCLC)患者的一线(1L)诱导或维持治疗的Ib/II期研究

2024-09-011
PRE
Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study

联合治疗与改善低密度脂蛋白胆固醇管理相关: 欧洲观察性圣托里尼研究的1年随访结果

2024-06-112
OA
Prognostic Value and Relative Cutoffs of Triglycerides Predicting Cardiovascular Outcome in a Large Regional-Based Italian Database

在基于区域的大型意大利数据库中预测心血管结果的甘油三酸酯的预后价值和相对临界值

2024-02-064
OAAI
ANGPTL3 Deficiency and Risk of Hepatic Steatosis
2023-11-077
PRE
Clinical Approach in the Management of Paediatric Patients with Familial Hypercholesterolemia: A National Survey Conducted by the LIPIGEN Paediatric Group
2023-08-051
OAAI
Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study
2023-06-01106
OA
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
2023-05-0289
OAAI